子宫内膜微生物群——新晋关键角色
综述指出,分子技术可检测既往视为无菌的子宫内膜低生物量微生物群,异常子宫内膜微生物群与种植失败、妊娠丢失及其他妇科和产科疾病相关;评估子宫内膜微生物群有望成为改善不孕患者生殖结局的未来工具。
要点
- 分子技术可检测子宫内膜低生物量微生物群。
- 异常子宫内膜微生物群与种植失败和妊娠丢失相关。
- 评估子宫内膜微生物群可能有助于改善不孕患者生殖结局。
核心结论
- 进一步研究生殖道微生物组有助于理解细菌群落的作用,从而影响妊娠的获得与维持。
- 评估子宫内膜微生物群有望成为改善不孕患者生殖结局的未来工具。
研究设计与样本
- 综述,围绕子宫内膜微生物群的现有文献进行总结。
主要发现
- 分子技术检测细菌使既往视为无菌的子宫内膜低生物量微生物群得以研究。
- 异常子宫内膜微生物群与种植失败、妊娠丢失及其他妇科和产科疾病相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Detection of bacteria with molecular techniques has enabled the study of low biomass microbiomes in tissues and organs previously considered sterile, such as the endometrium. Subsequently, an abnormal endometrial microbiota has been associated with implantation failure, pregnancy loss, and other gynecological and obstetrical conditions. Further investigation of the reproductive tract microbiome will allow for a better understanding of bacterial communities' role in both physiology and pathophysiology, which in turn impacts the ability to achieve pregnancy and maintain a healthy pregnancy. Here we review the current literature that surrounds the endometrial microbiome and highlight the importance of assessing it as a future tool for improving reproductive outcomes in infertile patients.
引用
- Moreno I, Franasiak JM. Endometrial microbiota-new player in town. Fertil Steril. 2017. PMID: 28602480. doi:10.1016/j.fertnstert.2017.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。